Review Proposes Chronic DNA Damage Signaling as an Aging Framework

A peer-reviewed review published in Aging on August 31, 2026, proposes that persistent overactivation of the DNA damage response may help connect several processes associated with biological aging. The proposed “guardian paradox” frames a possible biological tradeoff: cellular programs that protect against cancer and genomic instability may become harmful when chronically engaged, even if the underlying tumor-suppressor genes remain intact. Author Patrick E. Sewell organizes 16 candidate tumor suppressor–negative regulator axes into three evidence tiers and proposes experiments to determine whether persistent DNA damage response signaling is a cause, consequence or amplifier of aging. The review presents a research framework rather than a demonstrated treatment or an established account of aging.

The DNA damage response is a cellular surveillance system that detects genomic damage and coordinates repair. In young, healthy tissues, its signaling normally activates temporarily after stresses such as DNA double-strand breaks, replication stress or oxidative lesions and then subsides after repair. With aging, the review proposes that signals associated with telomere attrition, epigenetic erosion, mitochondrial dysfunction and transposable-element activity may maintain this response even without new driver mutations. In the proposed model, continued signaling stabilizes p53 and increases p21 and p16INK4a, encouraging cell-cycle arrest and cellular senescence. Senescent cells can then release inflammatory mediators through the senescence-associated secretory phenotype, or SASP.

SASP activity provides the proposed link between persistent DNA damage signaling and inflammation within tissues. Secreted mediators may spread senescence-associated signals to neighboring cells, reduce stem-cell function, disrupt tissue homeostasis and contribute to systemic inflammaging. The framework therefore does not require the relevant tumor-suppressor pathways to have been deleted or mutated; it allows for pathways that remain present but become persistently overactivated or otherwise dysregulated. In the review’s terminology, safeguards that protect younger tissues from damaged or potentially cancerous cells may become detrimental later in life. This is a proposed mechanistic link, not an observed clinical outcome, and the review supplies no integrated human intervention demonstrating that reducing chronic DNA damage signaling would slow aging.

The framework does not claim that chronic DNA damage signaling is the sole or necessarily earliest cause of aging. Sewell compares it with mitochondria-first, proteostasis-first and epigenetic-drift or reprogramming-centered models, acknowledging that mitochondrial dysfunction, impaired protein quality control or loss of epigenetic information could instead lie upstream. Somatic mutations are incorporated rather than dismissed. Clonal hematopoiesis of indeterminate potential, or CHIP, is discussed as a possible accelerating cofactor: age-acquired mutations in genes such as DNMT3A, TET2 and ASXL1 can promote clonal expansion of blood-cell populations. Within the proposed framework, CHIP may coexist with, and possibly intensify, dysregulation of DNA damage response pathways that is not primarily mutation-driven.

To organize the mechanisms, the review identifies 16 candidate tumor suppressor–negative regulator axes across three evidence tiers. The best-supported candidates named in the paper include p53/MDM2, p16INK4a/BMI-1, SIRT1/DBC1, telomerase/TRF1, PTEN/PI3K-AKT-mTOR and NRF2/KEAP1. Other candidate axes involve FOXO3, AMPK, Klotho, PGC-1α, TFEB and additional regulators. Evidence strength varies substantially among these pathways, and many proposed restoration strategies remain preclinical or conceptual. The review also introduces an Aging Axis Profile, or AAP, that would combine proteomic, transcriptomic, epigenomic, senescence and telomere measurements to characterize regulatory networks as functional, declining or dysfunctional. The author emphasizes that the AAP has not been analytically or clinically validated, and its proposed biomarker thresholds are illustrative rather than clinical cutoffs.

The proposed model connects DNA damage response signaling with several other regulatory systems rather than treating it as an isolated pathway. Persistent DDR activation and senescence-associated secretion form one feedback loop in the article’s schematic, with the SASP program potentially amplifying inflammatory signaling in neighboring cells. A second loop links NAD+ depletion and reduced sirtuin activity to impaired mitochondrial function, reactive oxygen species and feedback into DNA damage. A third connects reduced insulin/IGF-1 signaling, FOXO3, mTOR and autophagy, while a fourth relates declines in SIRT1 and heterochromatin integrity to transposable-element activity and cGAS–STING/interferon signaling. Shared nodes including DDR and SIRT1 couple the loops, and the proposed diagram also includes gut-barrier dysbiosis and LPS–TLR4/NF-κB signaling as an external amplifier. All restoration nodes in the schematic are explicitly illustrative and non-validated.

The review also considers how dysregulated pathways might eventually be brought closer to physiological states, but the proposed strategies remain theoretical or preclinical rather than established treatments. One approach would modulate endogenous negative regulators; in selected cases, the framework also considers AAV-based gene delivery. For chronically overactivated tumor-suppressor pathways such as p53 or p16, the theoretical objective would be to reduce persistent signaling without eliminating their cancer-protective functions. For protective pathways that decline with age, including SIRT1, FOXO3, NRF2 or Klotho, the proposed objective would be to restore physiological activity. These possibilities carry important safety concerns because excessive modulation of regulators such as MDM2, BMI-1 or NRF2 could increase oncogenic risk. The paper therefore emphasizes controlled expression, appropriate participant selection, CHIP screening, long-term cancer surveillance and extensive preclinical validation before human intervention could be considered.

A separate part of the review specifies how the central hypothesis could be tested rather than treated as established. Longitudinal studies could examine whether persistent DNA damage response activation precedes other age-related changes. Head-to-head experiments could compare interventions directed at DNA damage signaling with approaches targeting mitochondria, proteostasis or other processes. Such comparisons would help distinguish the model from competing explanations and could expose cases in which chronic signaling is downstream rather than causal. The review describes the framework as falsifiable because it identifies observations and comparisons that could challenge the proposal, while also stating that its present value lies mainly in research design. Candidate interventions, biomarker panels and restoration nodes would require evaluation against alternatives, with safety assessed over periods long enough to detect tumor-related effects.

Important limitations remain. There are no integrated human interventional data validating the framework as a whole, many individual axes are supported primarily by animal or in vitro evidence, and the Aging Axis Profile remains conceptual. Aging is multicausal and heterogeneous across tissues and individuals, so a process prominent in one setting may not be equally important elsewhere. Mitochondrial, proteostatic, metabolic or epigenetic mechanisms could ultimately prove more causally important than chronic DDR activation. The framework should therefore not be read as evidence that DNA damage signaling is the earliest or dominant cause of aging, nor as a clinical protocol. It is a structured proposal for organizing candidate mechanisms, identifying possible biomarker panels and specifying experiments capable of supporting or refuting its central claim.

Even with those caveats, the guardian paradox offers a compact way to examine a recognizable biological tradeoff. DNA damage response and tumor-suppressor programs protect cellular integrity when they operate temporarily, but persistent activation may help maintain senescence-associated inflammation and interfere with tissue renewal. The proposed 16-axis structure links that possibility to networks involving metabolism, mitochondrial function, autophagy, epigenetic control and inflammatory signaling. It also preserves a distinction often blurred in discussions of aging: the accumulation of mutations is one phenomenon, whereas sustained activity of intact repair and checkpoint systems is another. Whether the latter becomes a major driver, a downstream consequence or an amplifier remains unresolved. The review’s contribution is therefore not a proven intervention but a testable research agenda asking whether selected pathways can be measured, compared across competing models and, eventually, safely modulated without compromising tumor suppression.

Subject of Research: Review-based hypothesis that chronic DNA damage response signaling may contribute to biological aging.

Article Title: The “guardian paradox” links chronic DNA damage response to aging

Article References: The “guardian paradox” links chronic DNA damage response to aging. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: DNA damage response, biological aging, cellular senescence, inflammaging, tumor suppressor pathways, p53, SASP, mitochondrial dysfunction, epigenetic aging, clonal hematopoiesis, research framework, guardian